MECP2 Reactivation

This promising strategy aims to cure Rett by activating a backup copy of MECP2 present in all female cells.

What it is

Rett syndrome is caused by mutations in the MECP2 gene on the X chromosome. All females have two X chromosomes, one active and one inactive. In every cell where the mutated gene is active there is a healthy backup gene on the inactive X chromosome. The goal of this strategy is to awaken the healthy, silenced gene.

Why it's part of our plan

Activating MECP2 in enough cells could conceivably reverse Rett symptoms.

Challenges

The biggest challenge with this strategy is achieving sustained reactivation of the MECP2 gene in a sufficient number of cells to make a clinical impact.

Status

RSRT has been championing this strategy since our inception in 2008. Today we are funding two general paths to reactivation. The first is a drug intervention that would need to be given on an ongoing basis. The second involves altering cells in a specific way to encourage the reactivation of the silent MECP2 gene.

MECP2 Reactivation Awakens the Healthy Gene in Female Cells

Biologic Solutions to Reactivation

In recent years researchers from around the world generated additional data that made it possible to better understand how the X chromosome becomes inactivated. This additional data made it possible to begin designing biologic strategies for MECP2 reactivation. These strategies necessitate the ability to, first, target the specific spot on the X chromosome where the inactive MECP2 resides and, second, be able to bring molecules that can remove certain chemical tags from MECP2 that keep it silenced. The hope is to be able to effectively and efficiently deliver this therapeutic to the brain in a "one-and-done" manner.

MECP2 Reactivation Programs

RSRT has invested more than $7 million in MECP2 reactivation. RSRT-driven collaborations, initiatives, and investments have helped to generate all of the following MECP2 reactivation programs.

Alcyone Therapeutics

In March 2021 Alcyone Therapeutics announced their lead program, ACTX-101, a genetic strategy to reactivate the silenced MECP2 on the inactive X chromosome. Alcyone has partnered with two scientists, Sanchita Bhatnagar, PhD, and Kathrin Meyer, PhD, who began their Rett efforts with RSRT funding.

RSRT's Partnership with Alcyone

Alcyone’s Rett program, ACTX-101, was developed through a strong collaboration between leading scientists Dr. Kathrin Meyer and Dr. Sanchita Bhatnagar. Both scientists got their start in Rett through RSRT funding.
RSRT introduced the scientists to each other, which enabled their critical collaboration.

Watch: Cure 360 Webinar Series: Introducing ACTX-101, a Gene Therapy for Rett Using X Reactivation Technology

Herophilus

Herophilus, Inc. is a biotech company that employs human brain models, scaled biology and machine learning to discover and develop novel drugs for brain diseases. Their lead program is for Rett syndrome which advances HRP-12975, a small molecule therapy that reactivates the MECP2 gene on the silenced X chromosome.

RSRT's Partnership with Herophilus

Funding to Herophilus to support drug development of HRP-12975
Pioneering research by the MECP2 Reactivation Consortium funded by millions of dollars from RSRT made this approach realistic to pursue.
Access to RSRT’s biorepository of Rett cell lines enabled Herophilus to make Rett their lead program

The Labs of Kyle Fink, PhD, and Antonio Bedalov, PhD

Inactivation of the MECP2 gene on the silent X chromosome is maintained by several biological mechanisms. Two key mechanisms are the presence of an RNA called XIST, which surrounds the inactive X chromosome like a cloud, and DNA methylation marks on the inactive X chromosome. The Fink and Bedalov labs have obtained evidence that removal of DNA methylation marks, as well as the XIST RNA from the inactive X chromosome, has the potential to robustly turn on the silenced copy of MECP2.

The labs are employing CRISPR-Cas9 fused to an enzyme called TET1 that removes DNA methylation marks from the MECP2 gene. Prior work in the Fink laboratory has successfully used this epigenome editing approach to activate a silenced copy of CDLK5 on the inactive X chromosome in vitro as a potential treatment strategy for CDKL5-deficiency disorder, a genetic disorder that is similar to Rett syndrome. In addition, the scientists will combine this targeted approach with global down-regulation of XIST. The Bedalov lab has already shown that XIST deletion in the mouse brain is well tolerated and reactivates MECP2. Building on the expertise of the Fink and Bedalov laboratories, parallel studies are being pursued in human and mouse cells in vitro and in mouse Rett syndrome models in vivo by delivery of epigenetic editors via adeno-associated viral vectors, paving the way for future clinical trials in girls with Rett syndrome.

Kyle Fink's lab is at the University of California, Davis and Antonio Bedalov's lab is at the Fred Hutchinson Cancer Research Institute.

The Lab of Shawn Liu, PhD

It is a well known fact that about 20% of the genes on the inactive human X chromosome escape inactivation and are actively making protein. A common feature of these "escapee" genes is the unique physical structure of the DNA that surrounds them. The hypothesis is that the physical structure of the surrounding DNA helps to maintain gene activation.

Shawn Liu, PhD, theorized that by mimicking the DNA structure around the MECP2 gene he might coax the gene to stay active. He created the desired DNA structure by recruiting a protein called CTCF using CRISPR technology. He proposes a two-prong approach to MECP2 reactivation by combining the removal of methyl groups with the changing of the DNA structure around MECP2.

RSRT awarded funding to the Liu lab in 2022 to join the Bedalov/Fink collaboration. Each scientist brings unique resources to the collaboration – Liu brings the novel two-prong approach, Bedalov brings the mouse model he developed specifically for MECP2 reactivation experiments, and Fink brings the AAV packaging expertise.

Shawn Liu began his work on Rett as a post-doc in the RSRT-funded lab of Rudolf Jaenisch. In 2020 he transitioned to his own independent lab at Columbia University.

The Lab of Rudolf Jaenisch, PhD

Several years ago we began funding the lab of Dr. Rudolf Jaenisch, PhD, to pursue a novel approach to reactivation that leverages CRISPR technology to deliver certain epigenetic molecules to the inactive MECP2. The epigenome controls when genes are turned on or off by adding or removing chemical tags. One can think of the genome (DNA) as a charm bracelet and the epigenome as charms that can be added and removed. Methyl tags on DNA keep genes silent and acetyl tags keep genes active. The video below explains the experiments being pursued in the Jaenisch lab.

It’s important to note that biologic therapeutics will need to be delivered to the brain, and therefore our ongoing delivery efforts will be highly relevant to our reactivation program.

Watch: Jaenisch Lab Award

Gene Editing

RNA Editing